BRPI0519931A2 - métodos e composições para reduzir o dano microvascular derivado da isquemia - Google Patents

métodos e composições para reduzir o dano microvascular derivado da isquemia

Info

Publication number
BRPI0519931A2
BRPI0519931A2 BRPI0519931-0A BRPI0519931A BRPI0519931A2 BR PI0519931 A2 BRPI0519931 A2 BR PI0519931A2 BR PI0519931 A BRPI0519931 A BR PI0519931A BR PI0519931 A2 BRPI0519931 A2 BR PI0519931A2
Authority
BR
Brazil
Prior art keywords
methods
blood vessel
compositions
microvascular damage
event
Prior art date
Application number
BRPI0519931-0A
Other languages
English (en)
Inventor
Fumiaki Ikeno
Koichi Inagaki
Daria Mochly-Rosen
Mehrdad Rezaee
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of BRPI0519931A2 publication Critical patent/BRPI0519931A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODOS E COMPOSIçõES PARA REDUZIR O DANO MICROVASCULAR DERIVADO DA ISQUEMIA. São fornecidos métodos de diminuição da extensão da oclusão no lúmen de um vaso sangúíneo de um mamífero em conseqúência de um evento isquêmico ou de outro evento hipáxico. Em uma forma, um método inclui a administração de uma quantidade farmaceuticamente eficaz de um inibidor de <sym> proteína quinase C a um paciente que necessite desta, tanto isoladamente quanto em combinação com um segundo agente terapêutico, e em que o vaso sangúíneo é um vaso sangúíneo da microvasculatura. Adicionalmente, também são fornecidos métodos de diminuição do edema das células endoteliais em um vaso sangúíneo de um mamífero em conseqúência de um evento isquêmico ou de outro evento hipóxico. Em uma forma, um método inclui a administração de uma quantidade farmaceuticamente eficaz de um inibidor de <sym> proteína quinase C a um paciente que necessite desta, tanto isoladamente quanto em combinação com um segundo agente terapêutico.
BRPI0519931-0A 2005-01-26 2005-05-06 métodos e composições para reduzir o dano microvascular derivado da isquemia BRPI0519931A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64766405P 2005-01-26 2005-01-26
PCT/US2005/016114 WO2006080941A1 (en) 2005-01-26 2005-05-06 Methods and compositions for reducing ischemia-derived microvascular damage

Publications (1)

Publication Number Publication Date
BRPI0519931A2 true BRPI0519931A2 (pt) 2009-04-07

Family

ID=36740835

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519931-0A BRPI0519931A2 (pt) 2005-01-26 2005-05-06 métodos e composições para reduzir o dano microvascular derivado da isquemia

Country Status (6)

Country Link
US (1) US20090186814A1 (pt)
AU (1) AU2005325746A1 (pt)
BR (1) BRPI0519931A2 (pt)
CA (1) CA2594436A1 (pt)
MX (1) MX2007009115A (pt)
WO (1) WO2006080941A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US20090048174A1 (en) * 2006-12-08 2009-02-19 Mochly-Rosen Daria D Methods for inhibiting angiogenesis and tumor growth by inhibition of beta or delta protein kinase C
US20090062208A1 (en) * 2007-02-06 2009-03-05 Mochly-Rosen Daria D Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor
WO2010065479A2 (en) * 2008-12-01 2010-06-10 San Diego State University Foundation Compositions and methods using alpha beta-crystallin in protecting the myocardium from ischemia/reperfusion injury

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
WO1998017299A1 (en) * 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
US20020168354A1 (en) * 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US20050267030A1 (en) * 2004-04-30 2005-12-01 Tsao Philip S Use of deltaPKC peptides for modulation of reactive oxygen species
US20060148700A1 (en) * 2004-11-10 2006-07-06 Daria Mochly-Rosen Methods and compositions for reducing injury to a transplanted organ
EP1846016A2 (en) * 2005-01-04 2007-10-24 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow
WO2007027974A1 (en) * 2005-09-02 2007-03-08 The Board Of Trustees Of The Leland Stanford Junior University Method for reducing risk of and extent of injury due to stroke in hypertensive subjects

Also Published As

Publication number Publication date
US20090186814A1 (en) 2009-07-23
MX2007009115A (es) 2007-10-04
CA2594436A1 (en) 2006-08-03
WO2006080941A1 (en) 2006-08-03
AU2005325746A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
Sambo et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.
ME01133B (me) Kombinovana terapija sa peptidnim epoksiketonima
BR112013027674A2 (pt) &#34;usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha&#34;.
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
CU23821A3 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
WO2012006516A3 (en) Protein kinase c activators and anticoagulant for the treatment of stroke
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
CL2011000306A1 (es) Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion.
BRPI0518793A2 (pt) mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
BRPI0510110A (pt) método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
GT200900029A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
BR112012020731A2 (pt) pastilhas gelatinosas suaves com nicotina.
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
CO5590913A2 (es) Terapia de combinacion antivirica
MX384378B (es) Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
AR081439A1 (es) Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
AR065316A1 (es) Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales
NI201400122A (es) Agentes terapéuticos para administración subcutánea optimizados
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.